Bispecific Antibodies in DLBCL: Therapeutic Potential : comp

Robert Mancini, PharmD, discusses current DLBCL (diffuse large B cell lymphoma) management approaches, relapse rates, frontline, and subsequent therapies, including emerging treatments like bispecific T-cell engagers and monoclonal antibodies.

Related Keywords

Robert Mancini , , Emerging Role , Bispecific Antibodies , Diffuse Largeb Cell Lymphoma Management , Diffuse Largeb Cell Lymphoma , Dlbcl , Immunotherapy , Clinical Effectiveness , Safety Profiles , Multidisciplinary Care , Therapy Approaches , Relapse Rates , Emerging Treatments , Bispecifict Cell Engagers ,